U.S. Entertainment Stock News

Vericel stock has delivered a 32.0% return over the past year, yet its current valuation checks lean expensive, raising the question of how much of the story is already reflected in the share price. Over the last 1 year, Vericel has returned 32.0%. This puts recent shareholder gains front and center in any discussion of what the stock is worth today. For a company like Vericel, expectations around sustaining growth in its therapies can support the current pricing. However, any setback in...

Albertsons Companies stock has slipped over the past three years, even as some valuation checks now suggest the shares may be pricing in more caution than the current fundamentals alone would imply. Over the past three years, Albertsons Companies has delivered a total return that is down 25.4%. This puts recent price moves in the context of a longer period of weak shareholder outcomes. The push into AI-driven retail media through the Criteo integration can support margin and cash flow...

Molina Healthcare's stock has rallied strongly in the short term, yet the longer three year return is still deeply negative and the broader valuation checks lean expensive. This raises the question of how much of the Illinois Medicaid contract win is already reflected in the current price. Over the past three years, Molina Healthcare shares have declined 29.2%, which suggests that the recent strength is working off a weak longer term base rather than building on steady gains. The newly...

Watsco stock sits in an awkward spot on valuation today, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to almost 30% upside while traditional market multiples paint it as expensive and the broader checks give it a low value score. Watsco has returned 45.3% over the past 5 years, which is a solid outcome that makes the current price level important to scrutinize. Expectations for steady cash generation can support the DCF view of upside. However, any pressure on...

Regulatory shock puts Edwards Lifesciences stock under a sharper lens The Federal Trade Commission’s record $12 million penalty tied to Edwards Lifesciences (EW) acquisition of JC Medical, along with new restrictions on future TAVR AR deals, has pushed the stock’s regulatory risk profile into sharper focus. See our latest analysis for Edwards Lifesciences. Since the FTC action, Edwards Lifesciences’ recent 1 day share price return of 2.4% and 7 day return of 7.03% show selling pressure...

Recently, AXIS Capital Holdings’ strong track record of positive earnings surprises and a positive Zacks Earnings ESP of 3.82% highlighted rising analyst optimism ahead of its latest quarterly report. This pattern of earnings outperformance and upward estimate revisions has drawn attention to how consistently improving expectations can influence sentiment around the insurer’s near‑term performance. Next, we’ll examine how this positive earnings surprise momentum and analyst estimate...

We wouldn't blame Braze, Inc. ( NASDAQ:BRZE ) shareholders if they were a little worried about the fact that Astha...

Centrus Energy stock has delivered a very large 5 year gain, yet the current valuation checks lean expensive, with the broader model assigning it a low overall value score. Over the past 5 years, Centrus Energy has returned about 5.5x, which sets a high bar for any further upside to be justified by fundamentals. Future cash generation from its enrichment and fuel-related activities can support the current share price, but any setback to margins or project timing may quickly pressure what...

Softer than expected inflation data prompted investors to reassess interest rate expectations, and United Bankshares (UBSI) moved higher alongside regional peers as markets evaluated the potential for relief on funding costs and loan demand. See our latest analysis for United Bankshares. At a share price of $47.58, United Bankshares has a 1 month share price return of 7.67% and a year to date share price return of 23.94%. The 1 year total shareholder return of 32.45% and 5 year total...

Celcuity stock has delivered a very large 3 year return, yet its recent pullback and a mixed set of valuation checks raise questions about how much of the good news around its newly approved breast cancer therapy is already reflected in the price. Over the last 3 years Celcuity has returned roughly 7x, which sets a high bar for further gains given how much value has already been created for existing shareholders. The full FDA approval of REVTORPYK for advanced HR positive, HER2 negative...

We wouldn't blame Arista Networks, Inc. ( NYSE:ANET ) shareholders if they were a little worried about the fact that...

With tech stocks under pressure and expectations running high this earnings season, some investors are looking more closely at areas of the market that can sometimes feel steadier when sentiment turns cautious. This defensive sectors screener focuses on consumer staples, health care, and real estate companies that meet certain size and quality criteria, and are directly exposed to the latest news around earnings surprises, guidance resets, and interest rate expectations. In this article, you...

After roughly doubling over the past five years, ePlus stock now sits at a level where the Discounted Cash Flow (DCF) intrinsic value estimate suggests the shares trade at a premium. Broader valuation checks point to a more mixed picture rather than a clear warning sign. ePlus has returned about 102% over the past five years, so the stock is no longer an obvious bargain based purely on its recent track record. Strong recent momentum in the IT distribution and solutions business can support...

Anyone interested in FB Financial Corporation ( NYSE:FBK ) should probably be aware that the Chief Accounting Officer...

We can readily understand why investors are attracted to unprofitable companies. By way of example, Camp4 Therapeutics...

RenaissanceRe Holdings stock has delivered a 124.7% return over the past 5 years, and the current valuation checks indicate that the shares may still be inexpensive relative to the company’s fundamentals. RenaissanceRe Holdings' 124.7% 5-year return indicates that long-term holders have already seen solid gains, so any further upside may depend on whether current expectations for the business remain intact. For a reinsurer like RenaissanceRe Holdings, the outlook for underwriting...

We wouldn't blame Incyte Corporation ( NASDAQ:INCY ) shareholders if they were a little worried about the fact that...

Viewing insider transactions for Candel Therapeutics, Inc.'s ( NASDAQ:CADL ) over the last year, we see that insiders...

The new 25% US tariff on a broad range of Brazilian imports puts fresh attention on US Domestic Manufacturing stocks that could see shifts in demand, costs, or competitive positioning as supply chains adjust. With key Brazilian exports like coffee, beef, orange juice, and aircraft parts exempt, the impact is focused on other areas where domestic producers might gain or face new pressures. This article walks through 3 stocks from the US Domestic Manufacturing screener that appear positively...

Looking at Anteris Technologies Global Corp.'s ( NASDAQ:AVR ) insider transactions over the last year, we can see that...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Halliburton (NYSE:HAL) has secured multi-year contracts from Saudi Aramco covering unconventional gas development and onshore oil activities. The work includes deployment of Saudi Arabia’s first intelligent fracturing platform as part of a major unconventional gas project. The agreements also span a multi-year integrated oilfield program across hundreds of planned wells. Halliburton will expand local manufacturing and workforce commitments to support these projects. For investors watching...

ANI Pharmaceuticals has delivered a strong 139.1% return over the past 5 years, yet at around US$79.20 the valuation checks now suggest the stock is closer to fairly priced than obviously cheap. A 139.1% total return over 5 years indicates ANI Pharmaceuticals has already rewarded patient shareholders, so fresh buyers may be weighing how much of the story is reflected in the current price. Positive topline data from the SYNCHRONICITY trial can support expectations for the branded portfolio,...

Bell Canada has completed its first direct to device satellite ground station to support AST SpaceMobile's network in Canada. AST SpaceMobile secured new regulatory approval in New Zealand, expanding its potential service footprint. The company is preparing for the launch of additional BlueBird satellites to build out its direct to device constellation. AST SpaceMobile (NasdaqGS:ASTS) is back in focus as it adds fresh infrastructure and regulatory pieces to its direct to device puzzle. The...